质子束治疗不可手术I-IIA期非小细胞肺癌的临床结局:日本全国登记研究
本研究基于日本质子束治疗全病例登记,纳入2016年5月至2020年6月起始质子束治疗的309例不可手术I-IIA期(UICC第8版)非小细胞肺癌患者。中位随访47个月,3年/5年总生存率62.7%/47.7%,无进展生存率52.9%/40.0%,局部失败累积发生率14.4%/22.1%。多因素分析显示女性、良好体能状态、无间质性肺炎、无双重癌及T1期是总生存的有利预后因素,未观察到≥4级不良事件。
要点
- 309例不可手术I-IIA期NSCLC接受质子束治疗,3年/5年OS为62.7%/47.7%。
- 3年/5年PFS为52.9%/40.0%,局部失败累积发生率14.4%/22.1%。
- 未观察到≥4级不良事件,女性、良好PS、无间质性肺炎、无双重癌及T1期为OS有利因素。
核心结论
- 本研究提供了日本不可手术I-IIA期非小细胞肺癌质子束治疗的真实世界治疗结局。
研究设计与样本
- 本研究为基于日本质子束治疗全病例登记的前瞻性观察研究,纳入2016年5月至2020年6月起始质子束治疗的309例不可手术I-IIA期(UICC第8版)非小细胞肺癌患者。
主要发现
- 中位随访47个月(采用反向Kaplan-Meier法计算),3年/5年总生存率为62.7%/47.7%,无进展生存率为52.9%/40.0%,局部失败累积发生率为14.4%/22.1%。
- 按分期,IA期3年总生存率、无进展生存率、局部失败累积发生率分别为69.6%、58.7%、13.3%;IB期分别为55.3%、41.6%、15.6%;IIA期分别为33.9%、41.5%、25.6%。
- 多因素分析显示,女性、良好体能状态、无间质性肺炎、无双重癌及T1期是总生存的有利预后因素。
- 未观察到≥4级不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiotherapy is the standard treatment for unresectable stage I-IIA non-small cell lung cancer (NSCLC). One treatment option within radiotherapy is proton beam therapy (PBT). Currently, a prospective observational study is being conducted at all proton therapy centers in Japan as part of a proton beam all-case registry. This study aimed to evaluate the outcomes of PBT for inoperable stage I-IIA NSCLC. METHODS: We included patients with stage I-IIA (UICC 8th) NSCLC who had started PBT between May 2016 and June 2020. Overall survival (OS), progression-free survival (PFS), cumulative incidence of local failure (LF), and adverse events were evaluated. Prognostic factors were compared using log-rank test and Cox proportional hazards model. The cumulative incidence curves were compared using Gray's test. RESULTS: A total of 309 patients were evaluated. The median follow-up period was 47 months, calculated using the reverse Kaplan-Meier method. The 3/5-year OS was 62.7 %/47.7 %, PFS was 52.9 %/40.0 %, and LF was 14.4 %/22.1 %. According to the stage, 3-year OS, PFS, and LF were 69.6 %, 58.7 %, 13.3 %, respectively, for stage IA; 55.3 %, 41.6 %, 15.6 %, respectively, for stage IB; 33.9 %, 41.5 %, 25.6 %, respectively, for stage IIA. Female sex and good performance status, absence of interstitial pneumonia, absence of double cancer, and T1 stage were favorable prognostic factors for OS in a multivariate analysis. Grade ≥ 4 adverse events were not observed. CONCLUSION: This study provided real-world treatment outcomes of PBT for inoperable stage I-IIA NSCLC in Japan.
引用
- Nakamura M, Maruo K, Murakami M, et al. Clinical outcomes of proton beam therapy for inoperable stage I-IIA non-small cell lung cancer: Japanese nationwide registry study. Radiother Oncol. 2025. PMID: 40122285. doi:10.1016/j.radonc.2025.110868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。